Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(FY)Feb 1, 2025 | (Q4)Feb 1, 2025 | (Q3)Nov 2, 2024 | (Q2)Aug 3, 2024 | (Q1)May 4, 2024 | (FY)Feb 3, 2024 | (Q4)Feb 3, 2024 | (Q3)Oct 28, 2023 | (Q2)Jul 29, 2023 | (Q1)Apr 29, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -34.66%34.15M | -23.34%52.82M | -106.09%-2.54M | 186.76%18.52M | 6.31%-34.65M | 11.69%52.27M | 113.42%68.9M | 537.28%41.69M | -186.03%-21.34M | -119.59%-36.99M |
Net income from continuing operations | -14.01%-33.06M | 0.18%-8.72M | 72.65%-364K | -79.62%-5.91M | -15.52%-18.07M | -171.57%-29M | -179.24%-8.74M | -110.34%-1.33M | -122.50%-3.29M | -882.73%-15.64M |
Operating gains losses | --612K | --111K | --28K | --457K | --16K | ---- | ---- | ---- | ---- | ---- |
Depreciation and amortization | 3.82%40.5M | -5.99%9.96M | -6.37%9.98M | 13.30%10.16M | 18.33%10.39M | 22.76%39.01M | 20.92%10.6M | 36.03%10.66M | 15.52%8.97M | 18.50%8.78M |
Deferred tax | 114.44%1.45M | 348.92%8.43M | 113.06%558K | -53.83%-2.07M | -420.67%-5.47M | -366.91%-10.05M | -164.46%-3.39M | -496.51%-4.27M | -166.47%-1.34M | -294.74%-1.05M |
Other non cash items | -49.73%8.67M | 170.94%5.22M | -46.27%6.4M | -97.78%202K | -187.81%-3.15M | -40.02%17.25M | -198.70%-7.35M | 130.04%11.92M | -27.37%9.11M | -0.33%3.59M |
Change In working capital | -61.88%11.75M | -51.83%37.04M | -185.04%-20.2M | 140.25%14.45M | 42.35%-19.55M | 149.14%30.81M | 5,766.03%76.89M | 220.46%23.75M | -235.92%-35.91M | -9.61%-33.91M |
-Change in receivables | -332.84%-290K | -197.87%-963K | 356.50%849K | 45.66%-194K | 104.96%18K | 42.24%-67K | 367.39%984K | -246.46%-331K | 45.66%-357K | -153.15%-363K |
-Change in inventory | -71.29%12.75M | 4.98%96.18M | -789.38%-74.7M | 128.79%28.21M | 47.51%-36.93M | 453.42%44.42M | 6.49%91.61M | 122.68%10.84M | 1,406.04%12.33M | -41.07%-70.36M |
-Change in prepaid assets | -46.30%1.12M | -90.48%904K | 8.57%-2.78M | 141.83%2.16M | 6.74%839K | 4,650.00%2.09M | 398.52%9.5M | -285.63%-3.04M | -1,160.49%-5.15M | -22.49%786K |
-Change in payables and accrued expense | 289.45%12.68M | -87.52%-53.18M | 283.64%64.7M | 61.46%-13.95M | -63.15%15.11M | 58.36%-6.69M | 61.17%-28.36M | -42.58%16.86M | -2,169.30%-36.19M | 58.66%41M |
-Change in other current liabilities | -79.31%-14.59M | -375.30%-6.62M | -49.05%-7.76M | 64.99%-1.68M | 373.52%1.48M | 67.90%-8.13M | 135.60%2.41M | -57.66%-5.21M | 21.28%-4.79M | 94.12%-540K |
-Change in other working capital | 108.44%68K | -4.14%717K | -110.83%-501K | 94.85%-90K | 98.69%-58K | 90.59%-806K | 118.46%748K | 3,403.03%4.62M | 66.67%-1.75M | -849.92%-4.43M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -34.66%34.15M | -23.34%52.82M | -106.09%-2.54M | 186.76%18.52M | 6.31%-34.65M | 11.69%52.27M | 113.42%68.9M | 537.28%41.69M | -186.03%-21.34M | -119.59%-36.99M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 81.88%-14.48M | 62.98%-3.23M | 81.15%-3.62M | 85.13%-4.34M | 85.55%-3.29M | -31.87%-79.9M | 60.54%-8.73M | -20.83%-19.2M | -175.94%-29.21M | -89.63%-22.76M |
Net PPE purchase and sale | 81.88%-14.48M | 62.98%-3.23M | 81.15%-3.62M | 85.13%-4.34M | 85.55%-3.29M | -31.87%-79.9M | 60.54%-8.73M | -20.83%-19.2M | -175.94%-29.21M | -89.63%-22.76M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 81.88%-14.48M | 62.98%-3.23M | 81.15%-3.62M | 85.13%-4.34M | 85.55%-3.29M | -31.87%-79.9M | 60.54%-8.73M | -20.83%-19.2M | -175.94%-29.21M | -89.63%-22.76M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -170.39%-19.98M | 17.56%-49.42M | 127.88%6.26M | -127.34%-13.78M | -38.79%36.97M | 169.50%28.38M | -479.53%-59.95M | -481.56%-22.47M | 176.48%50.41M | 104.51%60.39M |
Net issuance payments of debt | -168.47%-26.39M | -6.19%-57.06M | 129.38%6.58M | -124.95%-13M | -40.68%37.1M | 79.68%38.54M | -331.67%-53.73M | -236.52%-22.38M | 475.73%52.12M | 99.31%62.53M |
Net common stock issuance | --0 | 54.39%-208K | --0 | 113.03%208K | --0 | 95.76%-2.75M | 84.07%-456K | --0 | 96.90%-1.6M | ---696K |
Proceeds from stock option exercised by employees | -61.81%304K | ---- | ---- | ---- | ---- | -10.96%796K | ---- | ---- | ---- | ---- |
Net other financing activities | 174.41%6.11M | 214.94%7.54M | -238.04%-311K | -782.14%-988K | 90.87%-132K | -622.74%-8.21M | -261.09%-6.56M | 38.26%-92K | 77.91%-112K | 21.68%-1.45M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -170.39%-19.98M | 17.56%-49.42M | 127.88%6.26M | -127.34%-13.78M | -38.79%36.97M | 169.50%28.38M | -479.53%-59.95M | -481.56%-22.47M | 176.48%50.41M | 104.51%60.39M |
Net cash flow | ||||||||||
Beginning cash position | 31.48%3.14M | -8.54%2.67M | -11.51%2.56M | -28.68%2.17M | 31.48%3.14M | -95.81%2.39M | 13.87%2.92M | -51.93%2.89M | -94.73%3.04M | -95.81%2.39M |
Current changes in cash | -141.09%-309K | -26.55%166K | 381.82%106K | 366.67%392K | -249.46%-973K | 101.38%752K | 232.16%226K | 100.64%22K | 99.72%-147K | -5.24%651K |
End cash Position | -9.84%2.83M | -9.84%2.83M | -8.54%2.67M | -11.51%2.56M | -28.68%2.17M | 31.48%3.14M | 31.48%3.14M | 13.87%2.92M | -51.93%2.89M | -94.73%3.04M |
Free cash flow | 170.91%19.59M | -17.63%49.57M | -127.38%-6.16M | 127.98%14.14M | 36.46%-37.96M | -65.27%-27.63M | 729.93%60.18M | 340.63%22.49M | -455.46%-50.56M | -107.12%-59.74M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |